Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2016 - 2026)

Ironwood Pharmaceuticals' Current Deferred Revenue history spans 14 years, with the latest figure at $1.1 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 45.52% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 45.52% decrease, with the full-year FY2025 number at $1.1 million, down 45.52% from a year prior.
  • Current Deferred Revenue hit $1.1 million in Q4 2025 for Ironwood Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for IRWD hit a ceiling of $2.6 million in Q4 2023 and a floor of $978000.0 in Q2 2025.
  • Historically, Current Deferred Revenue has averaged $1.6 million across 3 years, with a median of $1.5 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: fell 22.44% in 2024 and later tumbled 45.52% in 2025.
  • Tracing IRWD's Current Deferred Revenue over 3 years: stood at $2.6 million in 2023, then fell by 22.44% to $2.0 million in 2024, then crashed by 45.52% to $1.1 million in 2025.
  • Business Quant data shows Current Deferred Revenue for IRWD at $1.1 million in Q4 2025, $1.0 million in Q3 2025, and $978000.0 in Q2 2025.